Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.
Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.
Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.
This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.
This report will inform you about Big Pharma鈥檚
38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their
The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of
So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.
This report also analyzes the financial 鈥瀖aturity鈥� of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem
5.1听听听听听听 Tumor Targeting & Effector Cell Engagement
5.2听听听听听听 Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies
5.3听听听听听听 Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies
5.4听听听听听听 Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies
5.5听听听听听听 Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies
5.6听听听听听听 Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies
5.7听听听听听听 Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies
5.8听听听听听听 Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies
5.9听听听听听听 Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies
7.1.听听听听听 Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies
7.2听听听听听听 Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
7.3听听听听听听 Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
7.4听听听听听听 Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
7.5听听听听听听 7.5 Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies
8.1听听听听听听 Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies听听听听听听听听听听听
8.2听听听听听听 Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies听听听听听听听听听听听
8.3听听听听听听 Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie
8.4听听听听听听 Novel 鈥濻pecial鈥� T-Cell and NK Cell Engaging Bispecific Antibody Technologies
9.1.1听听听 A-319
9.1.2听听听 A-337
9.1.3听听听 ABBV-428
9.1.4听听听 ABP-100
9.1.5听听听 ABP-110
9.1.6听听听 ABP-150
9.1.7听听听 AFM13
9.1.8听听听 AFM14
9.1.9听听听 AFM26
9.1.10听 ALG.APV-527
9.1.11听 AMG 160
9.1.12听 AMG 212
9.1.13听 AMG 330
9.1.14听 AMG 420
9.1.15听 AMG 424
9.1.16听 AMG 427
9.1.17听 AMG 562
9.1.18听 AMG 596
9.1.19听 AMG 673
9.1.20听 AMG 701
9.1.21听 AMG 757
9.1.22听 AMV564
9.1.23听 Anti-FLT3
9.1.24听 Anti-ROR1
9.1.25听 APVO436
9.1.26听 ARB-201
9.1.27听 Blincyto
9.1.28听 BMS-986277
9.1.29听 CB307
9.1.30听 CC-93269
9.1.31听 ERY974
9.1.32听 GBR1302
9.1.33听 GBR1342
9.1.34听 GBR1372
9.1.35听 GEM3PSCA
9.1.36听 GEM333
9.1.37听 GEN3013
9.1.38听 HPN217
9.1.39听 HPN328
9.1.40听 HPN424
9.1.41听 HPN536
9.1.42听 IGM2323
9.1.43听 IMC-C103C
9.1.44听 IMC-F106C
9.1.45听 IMCgp100
9.1.46听 IMCnyeso
9.1.47听 IPH61
9.1.48听 JNJ-63709178
9.1.49听 JNJ-6389808
9.1.50听 JNJ-64007957
9.1.51听 JNJ-64407564
9.1.52听 JNJ-67571244
9.1.53听 M701
9.1.54听 M802
9.1.55听 MCLA-117
9.1.56听 MCLA-145
9.1.57听 MG1122
9.1.58听 MGD006
9.1.59听 MGD007
9.1.60听 MGD009
9.1.61听 MGD014
9.1.62听 MO0310
9.1.63听 ND021
9.1.64听 NG-641
9.1.65听 OXS-1615
9.1.66听 OXS-3550
9.1.67听 OXS-C3550
9.1.68听 PF-06671008
9.1.69听 PF-06863135
9.1.70听 PRS-342
9.1.71听 REGN1979
9.1.72听 REGN4018
9.1.73听 REGN5458
9.1.74听 RG6026
9.1.75听 RG6160
9.1.76听 RG6194
9.1.77听 RG7802
9.1.78听 RG7827
9.1.79听 RG7828
9.1.80听 SAR440234
9.1.81听 TNB-383B
9.1.82听 TNB-486
9.1.83听 TNB-585
9.1.84听 TSA(1)-CD28 & TSA(2)-CD28
9.1.85听 VB-600
9.1.86听 XmAb13676
9.1.87听 XmAb14045
9.1.88听 XmAb18087
9.1.89听 XmAb23104
9.1.90听 Y111
Table 1听听听听听听听听听听 Big Pharma鈥檚 In-House and In-Licensed T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
Table 2听听听听听听听听听听 Big Pharma鈥檚 Preferences for T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
Table 3听听听听听听听听听听 Big Pharma鈥檚 Preferences for Half-Life Extension in T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 4听听听听听听听听听听 Big Pharma鈥檚 Preferred Targets for T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 5听听听听听听听听听听 Economic Terms of Big Pharma鈥檚 Collaboration & Licensing Agreements for T-Cell & NK Cell Engaging Bispecific Antibody Technologies
Table 6听听听听听听听听听听 Main Characteristics of Big Pharma鈥檚 T-cell Engaging Bispecific Antibody Technologies
Table 7听听听听听听听听听听 Safety and Effector Cell Features of Big Pharma鈥檚 T-cell Engaging Bispecific Antibody Technologies
Table 8听听听听听听听听听听 Overview of Applied Technology, Target and Highest R&D Phase of Big Pharma鈥檚 Proprietary T-cell and NK Cell Engaging Bispecific Antibodies
Table 9听听听听听听听听听听 Overview of Technology Companies with T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
Table 10听听听听听听听听 Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Ig-Based T-Cell or NK Cell Engaging Bispecific Technologies
Table 11听听听听听听听听 Overview of Targets and Highest R&D Phase of Ig-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 12听听听听听听听听 Overview of Partnering Deals of Technology Companies with Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 13听听听听听听听听 Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Fc-Based T-Cell or NK Cell Engaging Bispecific Technologies
Table 14听听听听听听听听 Overview of Targets and Highest R&D Phase of Fc-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 15听听听听听听听听 Overview of Partnering Deals of Technology Companies with Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 16听听听听听听听听 Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Binder-Based T-Cell or NK Cell Engaging Bispecific Technologies
Table 17听听听听听听听听 Overview of Targets and Highest R&D Phase of Binder-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 18听听听听听听听听 Overview of Partnering Deals of Technology Companies with Binder-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 19听听听听听听听听 Overview of Special Technology Companies for Safety Features and Mode of Cell Engagement of T-Cell or NK Cell Engaging Bispecific Technologies
Table 20听听听听听听听听 Overview of Targets and Highest R&D Phase of Various T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 21听听听听听听听听 Overview of Partnering Deals of Technology Companies with Various T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 22听听听听听听听听 Overview of Drug Profiles for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase
Table 23听听听听听听听听 Overview of Not Profiled Drug Candidates for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase
Table 24听听听听听听听听 Tumor Target, Effector Cell Engagement, Tumor Type and Number of Bispecific Antibodies per Phase of T-Cell and NK Cell Engaging Bispecific Antibodies
Table 25听听听听听听听听 Pipeline of BCMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 26听听听听听听听听 Pipeline of CD33-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 27听听听听听听听听 Pipeline of CD20-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 28听听听听听听听听 Pipeline of CD123-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 29听听听听听听听听 Pipeline of PSMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 30听听听听听听听听 Financing Sources of Technology Companies with Bispecific T-Cell and NK Cell Engaging Antibody Technologies
Table 31听听听听听听听听 Amgen鈥檚 Bispecific T-Cell Engager Pipeline
Table 32听听听听听听听听 Celgene鈥檚 Clinical Pipeline of Bispecific T-Cell Redirecting Antibodies
Table 33听听听听听听听听 Janssen鈥檚 Clinical Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 34听听听听听听听听 Pfizer鈥檚 T-cell Engaging Bispecific Antibody Pipeline
Table 35听听听听听听听听 Roche鈥檚 Pipeline of Clinical Stage T-Cell Redirecting Bispecific Antibodies
Table 36听听听听听听听听 Sanofi鈥檚 Bispecific T-Cell and NK Cell Engager Pipeline
Table 37听听听听听听听听 Abpro鈥檚 Pipeline of T-Cell Engaging TetraBi Antibodies
Table 38听听听听听听听听 Merus鈥� Biclonics Development Pipeline
Table 39听听听听听听听听 Regeneron Pharmaceuticals T-Cell Engaging Bispecific Antibody Pipeline
Table 40听听听听听听听听 TeneoBio鈥檚 Pipeline of T-Cell Engaging Bi- and Multi-Specific Human Heavy Chain Antibodies
Table 41听听听听听听听听 YZY Biopharma鈥榮 Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 42听听听听听听听听 Partnering Terms for Zymeworks鈥� Azymetric Technology
Table 43听听听听听听听听 Pipeline of ADAPTIR Molecules from Aptevo Therapeutics
Table 44听听听听听听听听 MacroGenics鈥� Clinical Stage Pipeline of T-Cell Redirecting Bispecific DART Antibodies
Table 45听听听听听听听听 Xencor鈥檚 Bispecific T-Cell Engaging Antibody Pipeline
Table 46听听听听听听听听 Generon鈥檚 Pipeline of Bispecific ITab Antibodies
Table 47听听听听听听听听 Harpoon Therapeutics鈥� TriTAC Pipeline
Table 48听听听听听听听听 Affimed Therapeutics鈥� T-Cell and NK-Cell Engaging Antibody Pipeline
Table 49听听听听听听听听 GT Biopharma鈥� Pipeline of Tri- and Tetra-Specific NK Cell Engagers
Table 50听听听听听听听听 Goals and Terms of Immunocore鈥檚 Industry Partnering Deals for ImmTAC Technology
Table 51听听听听听听听听 Immuncore鈥檚 Wholly Owned and Partnered Development Pipeline of ImmTACs
Table 52听听听听听听听听 Blincyto Global Sales
Table 53听听听听听听听听 Clinical Studies with IMCgp100
听
听
*If Applicable.